Weekly Research Analysts’ Ratings Changes for STAAR Surgical (STAA)

A number of firms have modified their ratings and price targets on shares of STAAR Surgical (NASDAQ: STAA) recently:

• 4/22/2026 – STAAR Surgical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/11/2026 – STAAR Surgical was upgraded by Wall Street Zen to “hold”.
• 4/9/2026 – STAAR Surgical had its price target raised by Wedbush from $21.00 to $26.00. They now have a “neutral” rating on the stock.
• 4/9/2026 – STAAR Surgical was upgraded by Canaccord Genuity Group Inc. from “hold” to “buy”. They now have a $27.00 price target on the stock, up from $22.00.
• 3/5/2026 – STAAR Surgical had its price target lowered by Wells Fargo & Company from $30.75 to $16.00. They now have an “equal weight” rating on the stock.
• 3/4/2026 – STAAR Surgical had its price target lowered by Stifel Nicolaus from $19.00 to $18.00. They now have a “hold” rating on the stock.

Insider Buying and Selling

In other news, Director Broadwood Partners, L.P. bought 316,017 shares of the company’s stock in a transaction on Friday, March 13th. The stock was purchased at an average cost of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares of the company’s stock, valued at $300,064,699.62. This trade represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought 670,213 shares of company stock valued at $12,266,249 in the last ninety days. 0.59% of the stock is currently owned by company insiders.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.